Cantor Fitzgerald Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on Crinetics Pharmaceuticals (CRNX) and raises the price target from $50 to $65.
March 04, 2024 | 3:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on Crinetics Pharmaceuticals and raises the price target from $50 to $65.
The increase in price target from $50 to $65 by a reputable analyst firm like Cantor Fitzgerald suggests a strong bullish outlook on Crinetics Pharmaceuticals. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in CRNX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100